FDA Approves Tafasitamab-cxix for Relapsed or Refractory Follicular Lymphoma By Ogkologos - August 14, 2025 617 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the inMIND study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Reunión anual de la American Society of Clinical Oncology de 2022:... June 5, 2022 Clinics Offering “Mammoglam” Services to Encourage More Women to Get Mammograms June 12, 2019 Obesity and Alcohol Are Contributing to Increases in Bowel Cancer Rates... January 29, 2024 ESMO Immuno-Oncology Congress 2024, Geneva, Switzerland, 11-13 December December 2, 2024 Load more HOT NEWS Study Identifies Potential Warning Signs of Colorectal Cancer in Younger Adults EMA Recommends Extension of Therapeutic Indications for Niraparib / Abiraterone Acetate Hope and Challenge: The NCI Annual Plan and Budget Proposal for... N-of-1 Tailored Combination Therapy Matched to the Molecular Alterations, Facilitated by...
